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ABSTRACT	
Three	oral	 platelet	 P2Y12	 inhibitors,	 clopidogrel,	 prasugrel	 and	 ticagrelor,	 are	 available	 for	
reducing	 the	 risk	 of	 cardiovascular	 death	 and	 stent	 thrombosis	 in	 patients	 with	 acute	
coronary	syndromes	(ACS).	We	sought	to	compare	the	efficacy	of	these	antiplatelet	drugs	in	
contemporary	practice.	
Data	were	collected	for	10,793	consecutive	ACS	patients	undergoing	coronary	angiography	
at	 Sheffield,	 UK	 (2009-2015).	 Since	 prasugrel	 use	 was	 mostly	 restricted	 to	 the	 STEMI	
subgroup,	clopidogrel	and	ticagrelor	were	compared	for	all	ACS	patients	and	all	three	agents	
were	 compared	 in	 the	 STEMI	 subgroup.	 Differences	 in	 outcomes	 were	 evaluated	 at	 12	
months	by	KM	curves	and	log-rank	test	after	adjustment	for	independent	risk	factors.	
Of	 10,793	 patients	 with	 ACS	 (36%	 STEMI),	 43%	 (4653)	 received	 clopidogrel,	 11%	 (1223)	
prasugrel	and	46%	(4917)	ticagrelor,	with	aspirin	for	all.	In	the	overall	group,	ticagrelor	was	
associated	with	lower	all-cause	mortality	compared	with	clopidogrel	(adjusted	hazard	ratio	
(adjHR)	0.82,	95%	confidence	intervals	(CI)	0.71-0.96,	p	=	0.01).	In	the	STEMI	subgroup,	both	
prasugrel	and	ticagrelor	were	associated	with	a	lower	mortality	compared	with	clopidogrel	
(prasugrel	vs	clopidogrel:	adjHR	0.65,	CI	0.48-0.89,	p	=	0.007;	ticagrelor	vs	clopidogrel:	adjHR	
0.70,	 CI	 0.61-0.99,	 p	 =	 0.05).	 Of	 the	 7,595	 patients	 who	 underwent	 PCI,	 78	 (1.0%)	 had	
definite	 stent	 thrombosis	 by	 12	 months.	 Patients	 treated	 with	 ticagrelor	 had	 a	 lower	
incidence	 of	 definite	 stent	 thrombosis	 compared	 with	 clopidogrel	 (0.6%	 vs.	 1.1%;	 adjHR	
0.51,	 CI	 0.29-0.89,	 p=0.03).	 In	 the	 STEMI	 subgroup,	 there	 was	 no	 significant	 difference	
between	the	three	groups	(ticagrelor	1.0%,	clopidogrel=1.5%,	prasugrel=1.6%;	p=0.29).		
In	 conclusion,	 ticagrelor	 was	 superior	 to	 clopidogrel	 for	 reduction	 of	 both	 mortality	 and	
stent	 thrombosis	 in	 unselected	 invasively-managed	 ACS	 patients.	 In	 STEMI	 patients,	 both	
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ticagrelor	 and	 prasugrel	were	 associated	with	 lower	mortality	 compared	with	 clopidogrel	
but	there	was	no	significant	difference	in	the	incidence	of	stent	thrombosis.	
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INTRODUCTION	
Antiplatelet	agents	are	the	mainstay	of	treatment	for	patients	with	acute	coronary	
syndromes	(ACS)	[1].	The	majority	of	patients	with	ACS	undergo	coronary	revascularization	
with	percutaneous	coronary	intervention	(PCI)	or,	less	frequently,	coronary	artery	bypass	
graft	surgery	(CABG)	[2,	3].	Antiplatelet	therapy	is	vital	in	these	patients	to	prevent	future	
ischaemic	events	and,	in	PCI-treated	patients,	stent	thrombosis	[4-8].	The	choice	of	
antiplatelet	agents	for	patients	with	ACS,	especially	those	with	ST-segment	elevation	
myocardial	infarction	(STEMI),	remains	debatable.	It	is	recommended	that	all	these	patients	
should	receive	dual	antiplatelet	therapy	for	at	least	12	months	[1].	Aspirin	should	be	
continued	indefinitely	and	low	dose	(75-100	mg	daily)	is	preferred	over	higher	doses.	
Clopidogrel,	a	P2Y12	inhibitor,	was	the	commonly	used	2
nd
	antiplatelet	agent	in	the	last	
decade.	However,	it	is	a	pro-drug	which	requires	hepatic	activation	by	the	cytochrome	P450	
system	and	some	patients	produce	ineffective	levels	of	active	metabolite	leading	to	poor	
pharmacodynamic	response	or	‘resistance’	[9].	Consequently,	newer	P2Y12	inhibitors,	
prasugrel	and	ticagrelor,	have	been	developed	in	recent	years	[9].	Prasugrel	therapy,	
compared	with	clopidogrel,	in	ACS	patients	undergoing	PCI	has	significantly	reduced	rates	of	
ischaemic	events,	including	stent	thrombosis,	but	with	an	increased	risk	of	bleeding	and	no	
significant	effect	on	1-year	mortality	[10].	Ticagrelor,	a	non-thienopyridine	P2Y12	inhibitor,	is	
an	active	drug,	which,	following	intestinal	absorption,	can	rapidly	achieve	adequate	levels	of	
platelet	inhibition.	The	PLATO	trial	has	shown	that	ticagrelor	reduces	1-year	mortality	in	
patients	with	ACS,	compared	with	clopidogrel	[11].	In	PLATO,	there	was	no	difference	in	
CABG-related	bleeding	with	ticagrelor	compared	with	clopidogrel	but	the	relative	increase	in	
non-CABG-related	bleeding,	including	those	managed	with	planned	invasive	strategy,	was	
similar	to	that	seen	previously	with	prasugrel	[11,	12].	However,	there	is	very	limited	data	on	
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comparison	of	newer	P2Y12	inhibitors	with	clopidogrel	in	unselected	ACS	patients	[13].	
Furthermore,	only	one	clinical	trial	with	a	modest	sample	size	(1230	patients)	has	directly	
compared	prasugrel	with	ticagrelor	and	this	has	shown	no	difference	in	outcomes,	although	it	
was	terminated	early	for	futility	[14],	and	the	results	of	further	comparative	efficacy	studies	
are	awaited	[15].	We	aimed	to	investigate	the	effect	of	the	introduction	of	prasugrel	and	
ticagrelor	on	all-cause	mortality	and	stent	thrombosis	in	this	large	single-centre,	all-comers	
registry.		
	
METHODS	
Study	design	and	population		
Data	were	collected	prospectively	for	consecutive	patients	attending	the	cardiac	
catheterization	laboratory	of	South	Yorkshire	Cardiothoracic	Centre	and	undergoing	
coronary	angiography	between	Jan	2009	and	June	2015	for	the	management	of	ACS.	This	
centre	is	the	only	one	providing	a	PCI	and	CABG	service	to	the	population	in	and	around	
Sheffield,	a	total	of	1.8	million	people.	For	patients	undergoing	PCI,	the	procedure	and	
adjunctive	pharmacotherapy	was	at	the	discretion	of	the	operator,	but	adhered	to	relevant	
local,	national,	and	international	guidelines.	Consequently,	there	was	a	gradual	evolution	of	
treatment	during	the	course	of	the	study	from	use	of	clopidogrel	as	the	only	P2Y12	inhibitor	
in	2009	to	introduction	of	the	option	of	prasugrel	in	2010,	predominantly	for	STEMI,	
followed	by	the	introduction	of	ticagrelor	as	first-line	therapy	in	February	2012,	according	to	
our	previously	published	protocols	that	included	the	prescription	of	high-intensity	statin	
therapy,	angiotensin	pathway	inhibitors	and	beta-blockers	throughout	the	study	period	
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[16].	Of	particular	note,	dual	antiplatelet	therapy	for	12	months	for	all	ACS	patients	was	the	
default	approach	throughout	the	study	period.	After	12	months,	patients	were	prescribed	
aspirin	indefinitely	and	so,	to	study	the	impact	of	dual	antiplatelet	therapy	on	clinical	
outcomes,	follow-up	was	limited	to	12	months.	Data	on	adherence	and	switching	of	
antiplatelet	therapy	were	not	collected	and	therefore	our	analysis	was	based	on	the	
intention	to	treat	patients	with	dual	antiplatelet	therapy	for	12	months.	The	groups	were	
defined	as	per	the	antiplatelet	agent	prescribed	on	admission	to	the	catheter	laboratory.	
Any	patient	who	had	an	event	whilst	in	hospital	resulting	in	a	change	of	antiplatelet	were	
defined	as	per	the	original	antiplatelet	prescribed.	Intra-procedural	unfractionated	heparin,	
and	not	bivalirudin,	was	the	default	anticoagulation	therapy,	along	with	selective	use	of	a	
glycoprotein	IIb/IIIa	inhibitor,	at	the	operators’	discretion.	All	patients	were	treated	with	2
nd
	
generation	drug-eluting	stents	or	bare-metal	stents,	at	the	operators’	discretion.	There	were	
no	exclusion	criteria.	There	was	increasing	provision	of	a	primary	PCI	service	to	the	
population	during	the	course	of	the	study,	accounting	for	a	higher	proportion	of	patients	
with	STEMI	in	the	later	years.	
Data	Collection		
Demographic,	clinical,	and	angiographic	data	were	collected	prospectively.	Renal	failure	was	
defined	as	creatinine	level	of	>200	μmol/L	and	cardiogenic	shock	as	systolic	blood	pressure	
<100	mmHg	along	with	signs	or	symptoms	of	hypoperfusion.	The	outcome	data	were	
collected	using	the	national	mortality	database	and	the	hospital	electronic	database	and	
patient	records	for	South	Yorkshire	Cardiothoracic	Centre.	Other	patient	records	were	not	
available	for	this	analysis	and	so	we	were	not	able	to	assess	non-fatal	ischaemic	and	
bleeding	outcomes.	The	Academic	Research	Consortium	(ARC)	criteria	were	used	to	define	
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definite	stent	thrombosis	[17]	and	our	data	were	based	on	the	assumption	that	survivors	of	
stent	thrombosis	would	present	or	be	referred	back	to	our	catheter	laboratory	since	this	is	
the	only	PCI	centre	for	the	region	and	there	was	no	change	in	this	arrangement	during	the	
course	of	the	data	collection.	The	cases	were	adjudicated	by	review	of	the	angiography	films	
by	two	cardiologists	independently	and,	in	cases	of	difference	of	opinion,	by	a	third	
cardiologist	as	a	referee.	
Data	analysis		
Data	are	presented	as	mean	±	SD	or	as	percentages	(proportions)	unless	stated	otherwise.	
Analysis	was	carried	out	using	Student’s	t-test	or	one-way	ANOVA	for	continuous	variables	
and	Chi-squared	or	Fisher’s	exact	test	for	categorical	variables.	Variables	with	significant	
trend	(p	≤	0.1)	were	entered	in	a	Cox	proportional	hazards	model	to	identify	factors	
independently	associated	with	mortality	and	stent	thrombosis.	Difference	in	outcomes	
among	patients	receiving	different	P2Y12	inhibitors	was	evaluated	by	Kaplan-Meier	survival	
curves	and	log-rank	test.	Clopidogrel	and	ticagrelor	were	compared	for	all	ACS	patients	and	
all	three	agents	were	compared	in	the	STEMI	subgroup.	All	statistical	analyses	were	
performed	using	SPSS	version	21	(IBM	SPSS	Inc.,	New	York,	USA)	and	R	software	version-
2.13.1	(R	Foundation	for	Statistical	Computing,	Vienna,	Austria).	
	
RESULTS	
Patient	Characteristics	
During	the	study	period,	10,793	patients	with	ACS	underwent	coronary	angiography.	The	
mean	age	was	63.6	±	12.7	years;	70%	of	the	patients	were	males	and	15%	had	diabetes.	
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About	two-thirds	(64%)	of	the	procedures	were	performed	for	non-ST	elevation	acute	
coronary	syndrome	(NSTE-ACS)	and	the	remaining	(36%)	were	for	STEMI.	Of	all	ACS	
patients,	43%	(n=4653)	received	clopidogrel,	46%	(n=4917)	received	ticagrelor	and	11%	
(n=1223)	received	prasugrel.	Of	the	prasugrel-treated	patients,	93%	(n=1136)	had	STEMI	
and	only	7%	(n=87)	had	NSTE-ACS	so	only	the	STEMI	cohort	was	included	in	the	analyses.	
ACS	patients	treated	with	clopidogrel	were	slightly	older	but	less	frequently	had	STEMI	or	
renal	failure	compared	to	those	treated	with	ticagrelor	(Table	1).	This	partly	reflected	an	
increasing	provision	of	primary	PCI	for	STEMI	during	the	years	in	which	prasugrel	and	then	
ticagrelor	were	introduced	as	options.	
Of	the	3920	(36%)	of	patients	who	underwent	coronary	angiography	for	STEMI,	the	mean	
age	was	62.9	±	12.9,	73%	were	male	and	12%	had	diabetes.	29%	(n=1130)	received	
clopidogrel,	29%	(n=1136)	prasugrel	and	42%	(n=1654)	ticagrelor.	Differences	were	noted	in	
some	clinical	characteristics	between	the	three	groups	(Table	2):	prasugrel-treated	patients	
were	younger	and	clopidogrel-treated	patients	older	than	those	treated	with	ticagrelor;	
prior	history	of	stroke/TIA	was	more	common	in	clopidogrel-treated	patients;	and	
cardiogenic	shock	was	more	common	in	ticagrelor-treated	patients.	
All-cause	mortality	at	one	year		
Of	the	10,793	patients	with	ACS,	787	(7.3%)	died	within	one	year.	The	use	of	ticagrelor	was	
associated	with	significantly	lower	all-cause	mortality	at	1-year	compared	with	clopidogrel	
(Figure	1A).	The	use	of	clopidogrel	was	an	independent	risk	factor	for	mortality	in	multiple	
regression	analysis	(Table	3).	After	adjustment	for	the	independent	risk	factors,	there	was	
still	lower	mortality	in	patients	treated	with	ticagrelor	(Figure	1B).		
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Of	the	3920	patients	with	STEMI,	340	(8.7%)	died	within	one	year.	The	use	of	prasugrel	and	
ticagrelor	(vs	clopidogrel)	was	associated	with	significantly	lower	all-cause	mortality	at	1-
year	(Figure	1C).	After	adjustment	for	independent	risk	factors,	there	was	still	lower	
mortality	in	patients	treated	with	prasugrel	and	ticagrelor	compared	with	clopidogrel	
(Figure	1D).	
Incidence	of	definite	stent	thrombosis	
Out	of	all	ACS	patients,	7595	(70%)	were	treated	with	PCI.	Out	of	these	patients,	2880	(38%)	
patients	received	clopidogrel	and	3493	(46%)	ticagrelor.	The	remaining	1222	(16%)	received	
prasugrel.			
Among	PCI-treated	ACS	patients,	78	(1.0%)	developed	definite	stent	thrombosis	within	12	
months.	Of	these,	24	(31%)	were	acute	(<24	hours),	32	(41%)	subacute	(1-30	days)	and	22	
(28%)	late	(31-365	days).	Half	of	the	stent	thrombosis	events	in	patients	treated	with	
prasugrel	or	ticagrelor	were	acute	whereas	about	one-quarter	of	these	events	were	acute	in	
clopidogrel-treated	patients	(Table	4).	
The	use	of	ticagrelor	was	associated	with	a	lower	incidence	of	definite	stent	thrombosis	at	
one	year	compared	with	clopidogrel	(Figure	2A).	Clopidogrel	was	an	independent	risk	factor	
for	definite	stent	thrombosis	in	multiple	regression	analysis	(Table	5).	After	adjustment	for	
independent	risk	factors,	there	was	still	lower	risk	of	stent	thrombosis	in	ticagrelor-treated	
patients	(Figure	2B).	
Of	the	3881	patients	undergoing	PCI	for	STEMI,	51	(1.3%)	developed	stent	thrombosis	
within	12	months.	There	was	no	significant	difference	in	the	incidence	of	stent	thrombosis	
between	clopidogrel-,	prasugrel-	and	ticagrelor-treated	patients	in	unadjusted	(Figure	2C)	or	
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adjusted	analysis	(Figure	2D).	
	
DISCUSSION	
In	this	'real-world'	registry	of	10,793	patients	with	ACS,	we	found	that	ticagrelor	was	
associated	with	a	reduction	in	mortality	compared	with	clopidogrel	in	invasively-managed	
ACS	patients,	including	after	we	had	adjusted	for	differences	in	baseline	characteristics	that	
were	attributable	to	increasing	provision	of	primary	PCI	for	STEMI	during	the	study	period	
and	contraindications	to	the	use	of	ticagrelor	or	prasugrel.	Additionally,	both	ticagrelor	and	
prasugrel	were	associated	with	a	reduction	in	mortality	compared	to	clopidogrel	in	the	
STEMI	cohort.	In	all	ACS	patients,	ticagrelor	was	also	associated	with	lower	rates	of	stent	
thrombosis	compared	to	clopidogrel;	however,	there	was	no	significant	difference	in	the	
STEMI	subgroup.	
Dual	antiplatelet	therapy	in	the	form	of	aspirin	and	a	P2Y12	inhibitor	decreases	the	risks	of	
myocardial	infarction,	recurrent	ischaemia	and	cardiovascular	death	in	a	broad	spectrum	of	
ACS	patients	and	reduces	the	risk	of	stent	thrombosis	and	its	sequelae	in	PCI-treated	
patients	[18,	19].	The	original	dual	antiplatelet	regimen	consisted	of	aspirin	plus	ticlopidine,	
which	showed	superiority	to	aspirin	alone	or	aspirin	plus	warfarin	[20,	21].	Ticlopidine	fell	
out	of	favour	due	to	haematological	side-effects	and	was	replaced	by	the	safer	and	equally	
effective	alternative	of	clopidogrel	[18,	22].	However,	more	contemporary	concerns	of	
resistance	and	drug-drug	interactions	with	clopidogrel	have	led	to	the	development	of	the	
newer	oral	P2Y12	antagonists,	prasugrel	and	ticagrelor	[23,	24].	Prasugrel	is	a	pro-drug	
metabolized	to	its	active	form	by	CYP3A4	and	CYP2B6	with	a	more	rapid	onset	and	higher	
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mean	level	of	platelet	inhibition	compared	to	clopidogrel.		Patients	with	ACS	undergoing	PCI	
and	treated	with	dual	antiplatelet	including	prasugrel	had	lower	rates	of	myocardial	
infarction,	urgent	target-vessel	revascularization,	and	stent	thrombosis	as	compared	to	dual	
antiplatelet	therapy	with	clopidogrel	at	15-months	follow-up	of	their	index	PCI	in	TRITON-
TIMI-38	[10].	This	benefit	was	mostly	related	to	a	reduction	in	the	rates	of	non-fatal	
myocardial	infarction	(7.4%	with	prasugrel	vs	9.7%	with	clopidogrel;	HR	0.76;	95%	CI	0.67	to	
0.85;	P<0.001)	and	lower	rates	of	stent	thrombosis	(1.1%	vs	2.4%;	P<0.001).	Ticagrelor	is	a	
direct-acting,	reversibly-binding	agent	with	similarly	rapid	onset	of	action	compared	to	
clopidogrel	and	requires	twice-daily	administration.	In	the	PLATO	study,	among	patients	
with	ACS	treated	with	or	without	an	invasive	strategy,	there	was	a	reduction	in	the	
composite	endpoint	of	death	from	vascular	causes,	myocardial	infarction	or	stroke	when	
ticagrelor	was	included	in	the	dual	antiplatelet	therapy	regimen	as	compared	to	clopidogrel	
(9.8%	for	ticagrelor	vs	11.7%	with	clopidogrel;	HR	0.84;	95%	CI	0.77	to	0.92;	p<0.001)	[11].	
Ticagrelor	also	significantly	reduced	the	rate	of	stent	thrombosis	[25].	A	recent	meta-
analysis	of	the	randomized	trials	has	also	shown	the	beneficial	effect	of	new	P2Y12	inhibitors	
over	clopidogrel	[26].	The	SWEDEHEART	registry	confirmed	the	benefit	of	ticagrelor	(vs	
clopidogrel)	in	a	real-world	registry	of	45,073	patients	albeit	with	a	higher	bleeding	rate	
[13].		Our	data	from	a	large	all-comers	population	have	further	confirmed	the	benefit	of	
ticagrelor	in	all	ACS	patients	on	both	mortality	and	stent	thrombosis	that	was	seen	in	the	
clinical	trials	and	recent	registry.		
Both	prasugrel	and	ticagrelor	were	associated	with	reduced	mortality	compared	to	
clopidogrel	in	patients	with	STEMI,	however	there	was	no	significant	difference	between	the	
two	newer	agents	(Figures	1D	and	2D).	For	patients	with	NSTE-ACS,	ticagrelor	is	
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recommended	in	preference	to	clopidogrel	regardless	of	treatment	strategy	[1].	In	the	
PLATO	trial,	ticagrelor	was	superior	to	clopidogrel	for	patients	with	NSTE-ACS	whether	
treated	medically	or	with	revascularization	[27,	28].	Whereas	the	TRITON-TIMI	trial	showed	
benefits	of	prasugrel	compared	to	clopidogrel	in	patients	with	NSTE-ACS	treated	with	PCI,	
the	TRILOGY	ACS	trial	found	no	benefit	with	prasugrel	compared	to	clopidogrel	in	patients	
with	medically-treated	ACS	[29].	Consequently,	prasugrel	is	only	recommended	for	NSTE-
ACS	managed	with	PCI.	For	patients	with	STEMI	managed	with	primary	PCI,	both	prasugrel	
and	ticagrelor	are	recommended	in	preference	to	clopidogrel	for	patients	without	
contraindications	[3,	30].	Studies	of	platelet	reactivity	in	STEMI	patients	have	shown	similar	
onsets	of	action	of	prasugrel	and	ticagrelor	loading	doses,	with	evidence	of	both	being	
delayed	in	some	of	these	patients,	at	least	partly	due	to	morphine	treatment	[31-34].	We	
found	no	significant	difference	in	stent	thrombosis	rates	in	the	STEMI	group	with	the	newer	
P2Y12	inhibitors	(prasugrel	and	ticagrelor)	compared	to	clopidogrel.	Furthermore,	a	higher	
proportion	of	the	stent	thrombosis	seen	in	STEMI	occurred	acutely	(<24	hours)	(STEMI	45%,	
all	ACS	31%).	This	may	in	part	be	explained	by	the	increased	administration	of	morphine	in	
these	patients.	There	may	potentially	be	a	role	of	intravenous	P2Y12	inhibitors	in	these	
patients	[35,	36].		
Our	results	are	also	consistent	with	the	PRAGUE-18	study	[14],	where	1230	patients	
undergoing	primary	PCI	for	ACS	were	randomly	assigned	to	prasugrel	or	ticgarelor.	There	
was	no	significant	difference	in	the	primary	outcome	comprising	death,	re-infarction,	urgent	
target	vessel	revascularization,	stroke,	or	serious	bleeding	observed	at	30	days.	Currently	
most	centres	are	using	one	or	other	newer	P2Y12	inhibitor	for	patients	with	STEMI	treated	
with	primary	PCI;	however,	it	may	be	appropriate	to	have	both	drugs	available	and	use	one	
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or	the	other	based	on	clinical	profile	of	individual	patients	and	relative	contraindications	or	
side	effects	of	these	drugs.	Prasugrel	is	generally	not	recommended	in	older	(>75	years)	
patients	and	is	contraindicated	in	those	with	a	history	of	stroke,	whereas	ticagrelor	may	be	
avoided	in	patients	with	sinoatrial	node	dysfunction	untreated	with	permanent	pacemaker	
or	with	intolerable	dyspnoea	related	to	ticagrelor.		
Study	limitations:	This	is	an	observational	study,	with	the	data	derived	from	a	prospectively	
compiled	registry.	Data	for	bleeding	complications,	myocardial	infarction	or	stroke	were	not	
available	and	we	relied	on	referral	of	survivors	of	stent	thrombosis	back	to	our	PCI	centre	
for	recording	of	this	complication.	In	addition,	some	aspects	of	the	data	were	unconfirmed;	
for	example,	we	did	not	evaluate	patients’	adherence	to	their	antiplatelet	treatment	and	
our	results	are	based	on	antiplatelet	prescription	at	index	admission.	Rates	of	stent	
thrombosis	in	the	STEMI	subgroup	were	low	making	interpretation	difficult.	Because	of	the	
nature	of	the	registry,	we	did	not	include	ACS	patients	who	did	not	undergo	coronary	
angiography	and	so	our	results	only	provide	data	on	ACS	patients	who	are	managed	
invasively.	
Conclusion:	Ticagrelor	is	associated	with	improved	survival	and	a	reduction	in	stent	
thrombosis	compared	with	clopidogrel	in	invasively-managed	ACS	patients.	Both	ticagrelor	
and	prasugrel	are	associated	with	reduced	mortality	in	the	STEMI	cohort	compared	with	
clopidogrel	but	no	significant	difference	in	stent	thrombosis	was	seen	in	this	group.	Further	
head-to-head	comparison	of	prasugrel	and	ticagrelor	for	STEMI	patients	is	warranted	in	an	
adequately	powered	clinical	trial.	
	 	
14 
 
ACKNOWLEDGMENTS	
We	are	grateful	to	all	the	interventional	cardiologists	at	South	Yorkshire	Cardiothoracic	
Centre.	We	would	also	like	to	thank	Louisa	Alcock	for	help	with	data	extraction.	
	
	
DECLARATION	OF	INTEREST	STATEMENT	
RF	Storey	reports	research	grants,	consultancy	fees,	and	honoraria	from	AstraZeneca;	
research	grants	and	consultancy	fees	from	PlaqueTec;	and	consultancy	fees	from	Aspen,	
Bayer,	ThermoFisher	Scientific,	Bristol-Myers	Squibb/Pfizer	alliance,	and	The	Medicines	
Company.	The	other	authors	report	no	conflicts	of	interest.	
  
15 
 
FIGURE	LEGENDS	
	
	
Figure	1.	Cumulative	incidence	of	all-cause	mortality	over	1	year	showing	(A)	unadjusted	
rates	in	all	ACS	patients	treated	with	either	clopidogrel	or	ticagrelor,	(B)	adjusted	rates	in	all	
ACS	patients	treated	with	either	clopidogrel	or	ticagrelor,	(C)	unadjusted	rates	in	STEMI	
patients	treated	with	clopidogrel,	prasugrel	or	ticagrelor,	and	(D)	adjusted	rates	in	STEMI	
patients	treated	with	clopidogrel,	prasugrel	or	ticagrelor.	HR:	hazard	ratio;	CI:	confidence	
intervals.	
 
Figure	2.	Cumulative	incidence	of	definite	stent	thrombosis	over	1	year	showing	(A)	
unadjusted	rates	in	all	ACS	patients	treated	with	either	clopidogrel	or	ticagrelor,	(B)	
adjusted	rates	in	all	ACS	patients	treated	with	either	clopidogrel	or	ticagrelor,	(C)	
unadjusted	rates	in	STEMI	patients	treated	with	clopidogrel,	prasugrel	or	ticagrelor,	and	(D)	
adjusted	rates	in	STEMI	patients	treated	with	clopidogrel,	prasugrel	or	ticagrelor.	HR:	hazard	
ratio;	CI:	confidence	intervals.	
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Table	1:	Clinical	characteristics	of	all	ACS	patients	stratified	by	antiplatelet.	
 
Characteristic	 Clopidogrel	
N	=	4653	
Ticagrelor	
N	=	4917	
P	
Age	(years)	 64.4	(+/-12.9)	 63.5	(+/-12.7)	 <0.001	
Male	 3166	(68%)	 3466	(70%)	 0.009	
STEMI	 1130	(24%)	 1654	(34%)	 <0.001	
Renal	impairment	 45	(1%)	 107	(2%)	 <0.001	
Diabetes	mellitus	 687	(15%)	 798	(16%)	 0.05	
Previous	stroke/TIA	 143	(3%)	 144	(3%)	 0.68	
Previous	PCI	 320	(7%)	 359	(7%)	 0.42	
Previous	CABG	 149	(3%)	 141	(3%)	 0.34	
GP	IIb/IIIa	inhibitor	 581	(12%)	 634	(13%)	 0.55	
LMS	>50%	 340	(7.3%)	 226	(4.6%)	 <0.001	
Hypertension	 1882	(40%)	 2140	(44%)	 0.002	
Dyslipidaemia	(treated)	 2144	(46%)	 1903	(39%)	 <0.001	
3-vessel	disease	 1002	(22%)	 745	(15%)	 <0.001	
PCI	 2880	(62%)	 3353	(68%)	 <0.001	
		No.	of	vessels	attempted	 1.2	+/-	0.48	 1.2	+/-	0.47	 0.801	
		No.	of	stents	used	 1.59+/-	0.92	 1.47+/-	0.87	 <0.001	
Referred	for	CABG	 458	(10%)	 292	(6.2%)	 <0.001	
STEMI:	ST-elevation	myocardial	infarction;	TIA:	transient	ischaemic	attack;	PCI:	
percutaneous	coronary	intervention;	CABG:	coronary	artery	bypass	graft	surgery;		
GP:	glycoprotein;	LMS:	Left	main	stem	
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Table	2:	Clinical	characteristics	of	ST-elevation	myocardial	infarction	patients	according	to	
antiplatelet	therapy.	
 
TIA:	transient	ischaemic	attack;	PCI:	percutaneous	coronary	intervention;	CABG:	coronary	
artery	bypass	graft	surgery;	LMS:	Left	main	stem;	GP:	Glycoprotein	
 
  
Characteristic	 Clopidogrel	
N	=	1130	
Prasugrel	
N	=	1136	
Ticagrelor	
N	=	1654	
P	
Age	(years)	 65.2	+/-	13.7	 60.8	+/-	11.7	 62.8	+/-12.9	 <0.001	
Male	 804	(71%)	 870	(77%)	 1189	(72%)	 0.005	
Renal	impairment	 12	(1%)	 7	(1%)	 23	(1%)	 0.144	
Diabetes	mellitus	 141	(13%)	 121	(11%)	 216	(13%)	 0.147	
Hypertension	 413	(37%)	 388	(34%)	 593	(36%)	 0.477	
Dyslipidaemia	 444	(39%)	 419	(37%)	 470	(29%)	 <0.001	
Previous	stroke/TIA	 57	(5%)	 32	(2.8%)	 40	(2%)	 <0.001	
Previous	PCI	 76	(7%)	 78	(7%)	 139	(8%)	 0.172	
Previous	CABG	 19	(2%)	 16	(1%)	 24	(1%)	 0.805	
Cardiogenic	shock	 23	(2%)	 18	(2%)	 64	(4%)	 <0.001	
GP	IIb/IIIa	inhibitors	 391	(35%)	 364	(32%)	 529	(32%)	 0.299	
LMS	>50%	 61	(5.4%)	 31	(2.7%)	 53	(3.2%)	 0.001	
3-vessel	disease	 234	(21%)	 181	(16%)	 208	(13%)	 <0.001	
PCI	 1130	(100%)	 1135	(100%)	 1616	(98%)	 <0.001	
		No.	of	vessels	attempted	 1.12+/-	0.39	 1.10	+/-	0.35	 1.09	+/-	0.39	 0.139	
		No.	of	stents	used	 1.54+/-0.81	 1.50	+/-	0.82	 1.35+/-0.77	 <0.001	
Referred	for	CABG	 0	(0%)	 0	(0%)	 7	(0.4%)	 <0.001	
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Table	3:	Independent	predictors	of	mortality	in	all	acute	coronary	syndrome	patients	
	
Variable	 HR	 95%	CI	 p	
Cardiogenic	shock	 7.006		 5.247-9.353	 <0.001	
Renal	impairment	 3.048	 2.199	–	4.226	 <0.001	
Emergency	procedure	 2.396	 1.959	–	2.929	 <0.001	
LMS	disease	 1.693	 1.350	–	2.124	 <0.001	
3-vessel	disease	 1.358	 1.054-1.750	 0.02	
	Clopidogrel	 1.188	 1.020-1.382	 0.03	
Age	(years)	 1.057	 1.050	–	1.064	 <0.001	
STEMI	 0.805	 0.649-0.999	 0.05	
Dyslipidaemia	(treated)	 0.796	 0.681	–	0.932	 0.004	
LMS:	left	main	stem;	STEMI:	ST-elevation	myocardial	infarction	
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Table	4:	Incidence	and	timing	of	definite	stent	thrombosis	according	to	antiplatelet	therapy	
 
	 Clopidogrel	 Prasugrel	 Ticagrelor	 P	value	
All	PCI-treated	ACS	patients,	n	 2880	 -	 3353	  
	Definite	ST,	n	(%)	 33	(1.1%)	 - 21	(0.6%)	 0.02	
					Acute	(%	of	total)	 11	(33%)	 - 6	(29%)	 	
					Sub-acute	(%	of	total)	 15	(45%)	 - 5	(24%)	 	
					Late	(%	of	total)	 7	(21%)	 - 10	(48%)	 	
	     
All	PCI-treated	STEMI	patients,	n	 1130	 1136	 1654	  
	Definite	ST,	n	(%) 17	(1.5%)	 18	(1.6%)	 16	(1%)	 0.29	
					Acute	(%	of	total) 6	(26%)	 11	(61%)	 6	(38%)	  
					Sub-acute	(%	of	total) 7	(48%)	 5	(28%)	 4	(25%)	  
					Late	(%	of	total) 4	(26%)	 2	(11%)	 6	(38%)	  
PCI:	percutaneous	coronary	intervention;	ACS:	acute	coronary	syndromes;	ST:	stent	
thrombosis;	STEMI:	ST-elevation	myocardial	infarction	
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Table	5:	Independent	predictors	of	definite	stent	thrombosis	within	12	months	
 
Variable	 HR	 95%	CI	 p	
STEMI	 2.232	 1.286-3.872	 0.004	
Diabetes	 2.191	 1.189-4.037	 0.01	
Clopidogrel	 2.057	 1.187-3.565	 0.01	
Age	 0.967	 0.947-0.987	 0.001	
	STEMI:	ST-elevation	myocardial	infarction	
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